Page 234«..1020..233234235236..240250..»

Environmental Factor – September 2022: Extramural Papers of the Month – Environmental Factor Newsletter

Posted: September 8, 2022 at 2:27 am

ExtramuralBy Julie Leibach

Exposure to microcystin a toxin commonly released during harmful algal blooms can change the guts collection of microorganisms, or microbiome, and the associated abundance of antibiotic resistance genes, according to an NIEHS-funded study in mice.

Harmful algal blooms occur in water where nutrient runoff fuels the growth of toxin-producing organisms, such as microbes called cyanobacteria. Among the variety of toxins released by cyanobacteria, microcystin is the most prevalent. Routes of exposure include drinking or eating contaminated water or food, as well as skin contact.

For their study, the researchers exposed young mice to microcystin for two weeks. Then, they analyzed fecal and blood samples for the types of microbes and antibiotic resistance genes present. They found that exposure to microcystin caused a pronounced change in microbiome makeup and a notable decline in several beneficial gut bacteria compared with unexposed mice. That change correlated with an increase in the number and diversity of genes related to resistance to common antibiotics, such as tetracycline and macrolides. (Research has shown that antibiotic-resistance genes can be transferred from bacteria to host.)

Microcystin exposure also increased immune dysfunction in adult mice. Specifically, the team measured an increase in biological markers associated with immune system deterioration. They reported similar effects in mice designed to elicit human-like immune responses that typical lab mice might not reflect.

According to the authors, their study is the first to characterize the effect of microcystin on the immune system and on antimicrobial resistance. The findings have implications for which treatments are offered to people with other conditions who have also been exposed to the toxin.

Citation:Saha P, Bose D, Stebliankin V, Cickovski T, Seth RK, Porter DE, Brooks BW, Mathee K, Narasimhan G, Colwell R, Scott GI, Chatterjee S. 2022. Prior exposure to microcystin alters host gut resistome and is associated with dysregulated immune homeostasis in translatable mouse models. Sci Rep 12(1):11516.

Researchers funded by NIEHS identified understudied chemicals that frequently occur in the same products as those linked to breast cancer. These findings could inform studies looking at how exposure to chemical mixtures influences disease risk. The team focused on common exposure pathways, including food, pesticides, and personal care products, among others.

Breast cancer is the leading cause of cancer-related death among women worldwide. Only 10% of cases are attributed to genetic predisposition; the remainder stem from other risk factors, such as environmental exposures. However, data are scant regarding the role of chemical mixtures on breast cancer development.

The researchers first turned to a vast federal database that inventories chemicals used globally. For various compounds, they manually assigned key words related to 32 types of exposure pathways that people might encounter daily. Next, the team divided chemicals in the database into three categories: those with known breast cancer associations, those with no known association, and chemicals whose association with breast cancer had not been studied.

In total, the team assessed more than 6,300 understudied chemicals for co-occurrence with cancer-related compounds as well as for similarities between structure and chemical properties. Of those, they identified 50 understudied substances with chemical properties like those of cancer-linked agents that should be prioritized for additional toxicological and human studies.

The results highlight a need to consider chemical co-occurrence in mixtures especially when compounds share certain features when examining how everyday exposures influence breast cancer risk, according to the authors.

Citation:Koval LE, Dionisio KL, Friedman KP, Isaacs KK, Rager JE. 2022. Environmental mixtures and breast cancer: Identifying co-exposure patterns between understudied vs breast cancer-associated chemicals using chemical inventory informatics. J Expo Sci Environ Epidemiol; doi:10.1038/s41370-022-00451-8 [Online 16 June 2022].

Increased flooding from climate change in the U.S. will likely expose more people to legacy waste from former industrial sites, according to an NIEHS-funded study. Populations that face inequality stemming from racial, economic, and housing status are more likely to live in the areas that could be affected.

The researchers chose six urban centers located near coasts or along rivers that have experienced major industrial development and where legacy contamination has been documented. Those sites included populous areas in Rhode Island, Texas, Pennsylvania, Louisiana, Minnesota, and Oregon.

By examining state manufacturing directories spanning nearly 60 years, the team identified nearly 15,500 former industrial sites in certain sectors such as coal, petroleum, and rubber that were highly likely to be contaminated with waste considered harmful to humans. The researchers then estimated the future flood risk of those sites, drawing on data from the First Street Foundation, which makes projections based on multiple flood models.

All told, they identified 6,636 sites facing an elevated flood risk by 2050, and thousands to hundreds of thousands of people at risk of local exposure to contaminated floodwaters. Using data from the U.S. Census Bureau and guidance from the Centers for Disease Control and Prevention, the team also discovered that groups with higher measures of social vulnerability were overall more likely to live in those flood-prone areas.

The findings suggest that urban planning efforts should include strategies for remediation and engagement with residents of historically marginalized communities, the authors noted.

Citation:Marlow T, Elliot JR, Frickel S. 2022. Future flooding increases unequal exposure risks to relic industrial pollution. Environ Res Lett 17(7):074021.

The coronavirus that causes COVID-19 establishes infection by rewiring how cells make and process lipids, or fats, according to researchers funded in part by NIEHS. They also found that preventing cells from making certain fats stopped several coronavirus strains from proliferating.

First, the team explored how SARS-CoV-2 influences fat composition by exposing cells to live virus, as well as by altering cells to express individual virus proteins. Of hundreds of lipids analyzed, most revealed significant changes in structural and chemical properties after cells were exposed to the virus compared with unexposed cells. The researchers observed similar results in cells expressing virus proteins compared with cells without proteins.

Fats called triacylglycerols (TAGs) the most abundant fats in animal cells increased most substantially in response to infection. Further investigation showed a dramatic increase in TAG-related lipid droplets, which store fats, in cells expressing certain viral proteins. The researchers noted that those proteins may play a direct role in stimulating TAG production.

The team also evaluated the ability of fat-targeting compounds, such as weight-loss drugs, to stop infection. Drugs that inhibited pathways involved in TAG synthesis and breakdown successfully blocked viral proliferation. They were also effective against four coronavirus variants of concern, in addition to the original strain.

The array of lipid changes that occurred after infection indicates that SARS-CoV-2 affects fat metabolism in diverse ways, through multiple molecular mechanisms, according to the authors. Understanding cellular pathways that the virus needs for survival is a critical step toward developing targeted treatments.

Citation:Farley SE, Kyle JE, Leier HC, Bramer LM, Weinstein JB, Bates TA, Lee JY, Metz TO, Schultz C, Tafesse FG. 2022. A global lipid map reveals host dependency factors conserved across SARS-CoV-2 variants. Nat Commun 13(1):3487.

(Julie Leibach is a senior science writer at MDB, Inc., a contractor for the NIEHS Division of Extramural Research and Training.)

The rest is here:
Environmental Factor - September 2022: Extramural Papers of the Month - Environmental Factor Newsletter

Posted in Rhode Island Stem Cells | Comments Off on Environmental Factor – September 2022: Extramural Papers of the Month – Environmental Factor Newsletter

About Regenerative Medicine – Center for Regenerative Biotherapeutics …

Posted: September 8, 2022 at 2:24 am

Andre Terzic, M.D., Ph.D.

Center for Regenerative Biotherapeutics, Mayo Clinic

Andre Terzic, M.D., Ph.D.: Regenerative medicine is an exciting component of modern health care. It harnesses breakthroughs in technologies to address major unmet needs of the population, both nationally but also globally. With the successes of traditional medicine, we'll live longer. And aging has been viewed as a major triumph of humanity. At the same time, unfortunately, with aging, we are facing with a growing pandemic of so-called chronic diseases diseases that live with us throughout our lifespan, heart disease, cancer, diabetes and so on.

So regenerative medicine comes with this new ability to understand how our body can heal and to harness its innate ability, that self-ability to heal, to actually provide new solutions to these patients in need. So the Center for Regenerative Biotherapeutics at Mayo Clinic has been built to address the unmet needs of patients. It builds on our new knowledge, bringing new ways to promote the self-repair ability of our body.

There have been magic moments during these few decades that we have built the regenerative medicine field. One such moment was when we saw, for the first time, how out of a stem cell, we can create new beating heart tissue. It was a revolution for us.

We would like to bring now this knowledge that may have started in one field to build it across fields as the new science allows, essentially, for learning between fields. We need true, radical innovation to move the current knowledge into new solutions. That is where regenerative medicine has a unique role. It changes the way we treat patients.

The rest is here:
About Regenerative Medicine - Center for Regenerative Biotherapeutics ...

Posted in Regenerative Medicine | Comments Off on About Regenerative Medicine – Center for Regenerative Biotherapeutics …

Global Exosome Market Report 2022: Integration into Fields of Liquid Biopsy, Precision Medicine, and Regenerative Medicine Driving Growth -…

Posted: September 8, 2022 at 2:24 am

Dublin, Sept. 06, 2022 (GLOBE NEWSWIRE) -- The "The Global Exosome Market - Market Size, Forecast, Trials, and Trends, 2022" report has been added to ResearchAndMarkets.com's offering.

Exosome technologies have been developing rapidly in recent years and substantial growth is expected for the market as they get integrated into the fields of liquid biopsy, precision medicine, and regenerative medicine. In particular, cancer-derived exosomes influence the invasive potential of cells by regulating angiogenesis, metastasis, and immunity, making them an extremely useful source of biomarkers for use in cancer detection, diagnosis, and therapeutic selection.

The cargo contained within exosomes can offer prognostic information for a range of diseases - including cardiovascular, renal, neurodegenerative, and metabolic diseases - as well as cancer. Researchers investigating exosome biomarkers have discovered, identified, and reported the presence of hundreds of biomolecules within the lumen of exosomes. This discovery has compelled a rapid rise in exosome-related cancer biomarker research, including the use of exosomes for the detection, monitoring, and treatment of a diverse range of oncologic conditions.

Importantly, exosomes are present within a diverse range of biofluids, including serum, plasma, urine, seminal fluid, CSF, saliva, tears, and breast milk. For this reason, exosome-based diagnostics are minimally invasive, offering ease of use and speed of detection. Exosomes can also act as prognostic indicators and predictors of a patient's response to a specific course of treatment.

Exosomes are also being explored for their use as cell-free therapeutics. For example, if a patient has a disease caused by a missing or defective protein or microRNA, the patient's exosomes can be isolated, modified with the appropriate siRNA or protein, and injected back into the patient for treatment. Numerous approaches are being researched for creating drug-loaded exosomes and exosomes themselves can exert powerful effects. For example, mesenchymal stem cell (MSC) derived exosomes have the capacity to suppress inflammation, prevent scar tissue formation, and mediate a healthy immune response.

The Era of Exosomes

For these reasons, exosomes have gone from being overlooked to rapidly gaining momentum as a novel strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering cells to patients. Although exosomes were discovered more than 30 years ago, it was not until recently that the scientific community began to credit exosomes for a range of promising traits.

To date, three pharma companies (Takeda, Jazz Pharmaceuticals, and Roche Pharmaceutical Company) have signed partnership deals with exosome companies offering payment terms structured to deliver at or around $1 billion dollars. Within the past 5 years, there have been at least 7 partnership deals within the exosome industry, 8 large venture capital events, and 2 landmark acquisitions.

Today the exosome industry is witnessing:

Key Topics Covered:

1. REPORT OVERVIEW

2. EXOSOMES: AN OVERVIEW

3. EXOSOME ENGINEERING: THE NEW PLATFORM

4. MSC-DERIVED EXOSOMES IN REGENERATIVE MEDICINE

5. EXOSOME RESEARCH

6. COMMERCIALLY AVAILABLE EXOSOME RESEARCH TOOLS

7. SCIENTIFIC PUBLICATIONS IN EXOSOMES

8. EXOSOME PATENT LANDSCAPE

9. EXOSOMES: CLINICAL TRIAL LANDSCAPE

10. CURRENT STATUS OF EXOSOME MANUFACTURING

11. EXOSOME ISOLATION APPROACHES

12. DIAGNOSTIC APPLICATIONS OF EXOSOMES

13. THERAPEUTC APPLICATIONS OF EXOSOMES

14. APPLICATION OF EXOSOMES IN VACCINE DEVELOPMENT

15. CURRENT STATUS OF EXOSOME INDUSTRY

16. EXOSOME MARKET ANALYSIS

17. PROFILES OF EXOSOME MARKET COMPETITORSCompanies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/ekxak2

Go here to read the rest:
Global Exosome Market Report 2022: Integration into Fields of Liquid Biopsy, Precision Medicine, and Regenerative Medicine Driving Growth -...

Posted in Regenerative Medicine | Comments Off on Global Exosome Market Report 2022: Integration into Fields of Liquid Biopsy, Precision Medicine, and Regenerative Medicine Driving Growth -…

Addressing Diversity Barriers to Regenerative Medicine Free Press of Jacksonville – Jacksonville Free Press

Posted: September 8, 2022 at 2:24 am

Photo courtesy of Mayo

With the promise of regenerative medicine comes the risk of widening health care disparities. Sometimes the newest discoveries, such as regenerative interventions, are out of reach for people in diverse ethnic or socioeconomic groups or they may not understand or trust new options for healing.

Mayo Clinicis trying to overcome those barriers by launching community outreach and a bioethics study aimed at improving access to regenerative medicine among underserved groups.

Regenerative medicine sometimes could look like a science fiction movie. It is important to learn from the community about how things could be better explained to them or how we can erase any doubts that they have about what we do, says Jorge Mallea, M.D., a pulmonologist at Mayo Clinic in Florida. Listening to their concerns, and explaining what we know, the things still we dont have solutions for, and what we are trying to accomplish could improve understanding and engagement.

Regenerative medicine is an emerging field of practice that is shifting the focus of health care from fighting disease to rebuilding health, with an emphasis on repairing, replacing or restoring diseased cells and tissues. Mayo ClinicsCenter for Regenerative Medicineis at the vanguard of this movement, supporting the concept of regeneration for all. Dr. Mallea chairs the centers Equity, Inclusion and Diversity Advisory Committee.

More diverse clinical trials

To ensure that regenerative therapies go beyond selected or priority groups, Mayo Clinic is expanding the recruitment for clinical trials to include more diversity in race, age and socioeconomic status. For example, a dermatology study in Rochester is exploring how certain regenerative interventions might affect ethnic groups with different skin tones.

We want to learn more about diverse groups to ensure the therapies we apply would work for people of different genders, races and genetics, says Dr. Mallea. Its important to have representation from diverse groups. We could learn in our clinical trials that certain groups need different doses or distinct ways of applying the interventions.

In other research,Zubin Master, Ph.D., a bioethicist in Mayo ClinicsBiomedical Ethics Research Program, is leading a bioethics study that seeks to understand possible economic, social and ethnic barriers toplatelet-rich plasma platelets spun from a persons own blood and containing growth factors as an orthobiologic treatment for kneeosteoarthritis. Platelet-rich plasma is a new regenerative intervention that shows healing potential. However, the Food and Drug Administration has not yet approved it. Therefore, patients must pay out of pocket for it.

Mohamed Addani, aMayo Clinic Graduate School of Biomedical Sciencesstudent within Dr. Masters team, will interview patients across Mayo Clinic who choose platelet-rich plasma as an intervention for knee osteoarthritis and those who opt instead for standard care. The team will compare those responses to a more demographically diverse group of patients whove made similar care choices at Detroit Medical Center. Researchers will examine race, ethnicity, socioeconomic and demographic variables, beliefs, attitudes, and understanding of regenerative medicine.

This study will provide the first scientifically based data on whether health disparities exist among patients seeking next-generation regenerative interventions such as platelet-rich plasma, says Dr. Master. The results will give us the unique opportunity to identify factors that are creating barriers to regenerative care and proactively address ways to overcome them.

The project seeks to improve access and make regenerative medicine more equitable among diverse and underserved groups.

Showcasing the cool stuff

Attracting a more diverse pool of regenerative medicine scientists and practitioners is another strategy to boost inclusivity. Mayo Clinic is taking regenerative medicine on the road to high schools and colleges near its destination locations in Arizona, Florida and Minnesota, showcasing what Dr. Mallea describes as the cool stuff in research and development. The hope is that it might inspire students, particularly those from underrepresented and disadvantaged communities, to consider a career in regenerative medicine.

We are sharing examples of our research, such as bioprinting of organs and developing new medicines from living organisms like cells to fight different diseases and cancers, says Dr. Mallea. We hope to plant a seed in their minds that regenerative medicine holds promise not only as a future therapy, but also a future career.

In addition, Mayo is using the Community Scientist Program to open its doors to scientists from the community who want to learn more. This program pairs community scientists with regenerative medicine researchers. Mayo hopes these strategies will improve the interaction and understanding needed to ensure access to new regenerative therapies as they are introduced in the practice.

Envision yourself working for a global leader in an industry fueled by innovation and growth. Mayo Clinic has opportunities for you. Join us at Floridas No. 1 hospital by visiting https://jobs.mayoclinic.org/. For more information on health care topics please visit Mayo Clinic Jacksonville at mayoclinic.org.

View original post here:
Addressing Diversity Barriers to Regenerative Medicine Free Press of Jacksonville - Jacksonville Free Press

Posted in Regenerative Medicine | Comments Off on Addressing Diversity Barriers to Regenerative Medicine Free Press of Jacksonville – Jacksonville Free Press

Sernova Announces the Appointment of Daniel Mahony, Ph.D. to its Board of Directors – GlobeNewswire

Posted: September 8, 2022 at 2:24 am

- Successful biopharma entrepreneur with 25 years of experience growing leading healthcare firms -

LONDON, Ontario, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, today announcedthe appointment of Daniel Mahony, Ph.D. to its Board of Directors, effective September 30th, 2022. Dr. Mahony is Entrepreneur-in-Residence at Evotec and is also responsible for managing Evotecs equity investment portfolio.

Dr. Mahony brings over 25 years of global healthcare investment, management and research experience covering biotechnology, medical technology, and healthcare service sectors. Prior to joining Evotec, he served as the Co-head of Healthcare at Polar Capital where he launched the firms healthcare investment business in 2007 and grew it to over $4 billion of assets under management. Prior to Polar Capital, he was head of European healthcare research at Morgan Stanley, an analyst at ING Barings Furman Selz in New York, and a postdoctoral research scientist at DNAX Research Institute in California.

We are delighted to welcome Dr. Mahony to Sernovas Board of Directors, said Frank Holler, Executive Chair of Sernova. Dan has a unique background, starting as a research scientist, then moving into healthcare research and capital markets and finally into the pharmaceutical industry. This background gives him deep insights into the healthcare business and capital markets which will be very valuable for Sernova.

Dr. Mahony stated, Sernova is uniquely well positioned with its Cell Pouch System to become a leading player in regenerative medicine. I am thrilled to be joining its Board of Directors and look forward to working with the other directors and the management team to advance potential functional cures for some of the most challenging chronic diseases.

Dr. Mahony holds multiple industry leadership positions. He currently chairs the board of the BioIndustry Association (BIA), the industry trade association for UK life sciences,andholds non-executive directorships at the Wellcome Sanger Institute, Trellus Health, Celmatix, Keepabl, and Apian. Dr. Mahony also acts as a mentor for the NHS Clinical Entrepreneur Training Programme, which supports junior doctors and healthcare professionals in developing entrepreneurial aspirations during their clinical training. Dr. Mahony was awarded a first-class, honours degree in biochemistry from Oxford University and received his doctorate degree from Cambridge University. Dr. Mahony will replace Dr. Dohrmann as Evotecs representative on the Sernova board.

ABOUT SERNOVA CORP. AND THE CELL POUCH SYSTEM PLATFORM FOR CELL THERAPY

Sernova Corp. is a clinical-stage biotechnology company that is developing regenerative medicine therapeutic technologies for chronic diseases, including diabetes, thyroid disease, and blood disorders including hemophilia A. Sernova is currently focused on developing a functional cure for diabetes with its regenerative cell therapy platform technologies, including its proprietary Cell Pouch. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for long-term survival and function of therapeutic cells that release necessary proteins or factors missing from the body to treat chronic diseases. Sernovas Cell Pouch System has already shown it can potentially provide a functional cure to people with type 1 diabetes in an ongoing Phase 1/2 clinical study at the University of Chicago. Sernova is also advancing its proprietary conformal coating technology in collaboration with the University of Miami to cloak the therapeutic cells from the immune system attack with the goal to eliminate the need for chronic immunosuppressives. In May 2022, Sernova and Evotec entered into a global strategic collaboration to develop an implantable off-the-shelf iPSC-based (induced pluripotent stem cells) beta cell replacement therapy. This collaboration potentially provides Sernova an unlimited supply of insulin-producing cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2). Sernova is also gearing up to be in the clinic in two additional programs that utilize its Cell Pouch System an implantable cell therapy for benign thyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral factor VIII gene therapy for hemophilia A.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Corporate: Christopher Barnes VP, Investor Relations Sernova Corp. christopher.barnes@sernova.com Tel: 519-902-7923 http://www.sernova.com

Investors: Corey Davis, Ph.D. LifeSci Advisors, LLC cdavis@lifesciadvisors.com Tel: 212-915-2577

Media: Elizabeth Miller, M.D. LifeSci Communications emiller@lifescicomms.comTel: 646-791-9705

Here is the original post:
Sernova Announces the Appointment of Daniel Mahony, Ph.D. to its Board of Directors - GlobeNewswire

Posted in Regenerative Medicine | Comments Off on Sernova Announces the Appointment of Daniel Mahony, Ph.D. to its Board of Directors – GlobeNewswire

Looking to buy Mesoblast shares? Here’s the latest on where the ASX biotech is at with the FDA – The Motley Fool Australia

Posted: September 8, 2022 at 2:24 am

Image source: Getty Images

With the unwinding of the high-growth/tech trade of the past two years, many biotechnology names suffered equally in nasty selloffs this year.

Shares of Mesoblast Ltd(ASX: MSB) have taken a hit in 2022 having slipped more than 42% into the red this year to date.

Shares of the regenerative medicine player are currently at 84 cents apiece in early trading on Thursday, gaining the 3% they lost in yesterdays session.

It was a busy period in the last financial year for Mesoblast, especially in its liaison with the US Food and Drug Administration (FDA).

Mesoblast has made, and is set to make, a host of submissions to the FDA regarding its lead drug candidates, Remestemcel-L and Rexlemestrocel-L.

It intends to resubmit a biologics license application (BLA) with the FDA this quarter for the approval of Remestemcel-L in treating children with steroid-resistant acute graft-versus-host-disease (SR-aGVHD). It is aiming for this approval in early 2023.

Meanwhile, Mesoblast also plans to meet with the FDA in the next quarter under its existing regenerative medicine advanced therapy (RMAT) designation to discuss Rexlemestrocel-L.

They will look over data from the companys recent phase 3 trial of 565 patients with heart failure condition HFrEF.

Rexlemestrocel-L also gained alignment with the FDA last period on key metrics for a pivotal phase 3 clinical trial in patients with chronic low back pain (CLBP) associated with disc pathology.

This follows on from the first phase 3 trial covering the same condition and Mesoblast hopes to replicate favourable results produced there.

The company also plans to have received clearance from the FDA by the end of 2022 so it can commence the pivotal trial.

As such, it will be a busy few months for Mesoblast as it looks to progress through this next round of trials in both of its leading drug segments.

In the last 12 months, the Mesoblast share price has faltered 54% into the red.

More here:
Looking to buy Mesoblast shares? Here's the latest on where the ASX biotech is at with the FDA - The Motley Fool Australia

Posted in Regenerative Medicine | Comments Off on Looking to buy Mesoblast shares? Here’s the latest on where the ASX biotech is at with the FDA – The Motley Fool Australia

7.5 Million Granted to Collaborative PROTO Project led by Charit to Study Pluri’s PLX-PAD Cells for Osteoarthritis Treatment – GlobeNewswire

Posted: September 8, 2022 at 2:24 am

HAIFA, Israel, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (Pluri or the Company) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today announced that a 7.5 million non-dilutive grant from the European Unions Horizon Europe program has been awarded to PROTO (Advanced PeRsOnalized Therapies for Osteoarthritis), an international collaboration led by Charit, Berlin Institute of Health Center for Regenerative Therapies. The goal of the PROTO project is to utilize Pluris PLX-PAD cells in a Phase I/IIa study for the treatment of mild to moderate knee osteoarthritis (OA). The project is currently under grant agreement preparation number 101095635. Final approval of the grant is subject to completion of the consortium and Horizon Europe grant agreements. The funds from the grant are expected to be allocated between Pluri and other members of the consortium in accordance with budget and work packages which will be determined by the consortium.

The Phase I/IIa study will be carried out by Charit, Pluri and other members of the international consortium under the leadership of Professor Tobias Winkler, Principal Investigator (PI) at the Berlin Institute of Health Center for Regenerative Therapies, Julius Wolff Institute and Center for Musculoskeletal Surgery. Professor Winkler was also the lead PI in the Phase II and Phase III muscle regeneration studies using Pluris PLX-PAD cells.

Having evaluated PLX-PAD in other advanced-stage clinical studies, we see clear potential for this cell-based product to treat OA, Professor Winkler said. The immunomodulatory properties of PLX-PAD appear well suited to address the significant chronic inflammatory components that underly OA pathophysiology, and we are eager to advance the product candidate into a clinical study for this indication. Financial support from Horizon Europe may accelerate this critical process.

This award underscores the vast potential of our PLX-PAD cells to treat chronic disease with regenerative medicine, said Yaky Yanay, Pluris CEO and President. We are proud to expand our collaboration with Professor Winkler and Charit and receive support from Horizon Europe for our platform technology and cell product candidates, as we advance Pluris clinical pipeline and seek new cell-based solutions to longstanding health challenges.

OA is one of the most common chronic articular diseases, with a global prevalence of 16% in the adult population1. OA is the third most rapidly growing disease associated with disability2, showing an increase of 30% over the past decade, currently affecting more than 500 million people worldwide and about 50 million in Europe3. Globally, symptomatic OA affects ~10% of men and 18% of women over 60 years of age, with knee being most the commonly affected joint4. OA also represents a huge healthcare burden with U.S. indirect costs amounting to 1% of the gross national product5.

There is currently no effective disease-modifying treatment for OA, only symptomatic treatment at a late stage. OA increases the risks of joint inflammation, pain, stiffness, swelling, disability, morbidity and mortality, and it reduces quality of life and work performance. OA might lead to reduced mobility and chronic disability and is associated with cardiovascular and metabolic co-morbidities.

PLX-PAD is an innovative anti-inflammatory allogeneic placental cell therapy product candidate to treat patients with mild to moderate knee OA as a direct approach to reduce inflammation and cartilage degeneration.

________________1 Cui et al., 2020, PMID: 345058462 Hawker et al., 2019, PMID: 316215623 Hunter et al., 2020, PMID:331598514 A. Jaiswal et al., 20215 Kingsbury et al., 2014, PMID: 24489012

About Pluri Inc.Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Companys technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiativesfrom medicine and climate change to food scarcity, animal cruelty and beyond. Pluris method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine and food-tech and aims to establish partnerships that leverage the Companys 3D cell-based technology to additional industries that require effective, mass cell production. To learn more, visit us at http://www.pluri-biotech.com or follow us on LinkedIn and Twitter.

About Osteoarthritis and the ConsortiumOA is the most common form of arthritis worldwide. Chronic low-grade inflammation in the articular environment causes cartilage degeneration at an early disease stage, resulting in chronic pain, disability and loss of independence due to progressive joint destruction. To date, no disease modifying treatment is available to sustainably combat low-grade inflammation in early-stage OA patients. Biomechanical causes for intra-articular inflammation and OA development have been detected in specific patient groups. The PROTO consortium strives to implement new evidence- and patient-centered treatment strategies for early- and pre-disease stages. For the first time, early-stage knee OA patients will be treated with local PLX-PAD injections, a novel allogeneic cell therapy product with distinct anti-inflammatory capacities that may halt or revert disease progression. Secondly, patients recovering from anterior cruciate ligament reconstructions with pathological gait patterns leading to knee OA, will be treated with a personalized sensor-based digital training intervention. We intend to prevent health to disease transition by restoring physiological movement and reducing joint inflammation. To assess treatment success in early- and pre-stage OA, PROTO gathers scientific and clinical specialists who have genuinely shaped clinical, radiological and biomarker outcome parameters for OA in recent years. This will be the first time that these renowned experts join forces to analyze, stratify and compare fundamentally novel disease modifying treatment strategies for OA in one consortium. PROTO was developed with the help of patient organizations, industry partners and research societies. Restoring physiological joint homeostasis at an early disease stage may be the key to understanding health to disease progression in OA. Targeting this window of opportunity may fundamentally change the way OA is treated today and in the future.

Safe Harbor Statement This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses the expected receipt of the grant from the Israel Innovation Authority, the potential for PLX-PAD to be used to treat OA, that the receipt of the grant may accelerate the clinical study of PLX-PAD, that the grant underscores the potential for PLX-PAD cells to treat chronic disease and that it is advancing its clinical pipeline and seeking new cell-based solutions to longstanding health challenges, that targeting the current window of opportunity may fundamentally change the way OA is treated today and in the future and the potential of the Companys products and solutions to promote global wellbeing and sustainability. These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri reference is made to Pluri's reports filed from time to time with the Securities and Exchange Commission.

Media Contacts

Investors: investor.relations@pluri-biotech.com

Israel Media: Shachar Yental at shacharye@gitam.co.il

U.S. Media: Nathan Miller at nathan@miller-ink.com / Meira Feinman at meira@miller-ink.com

Go here to see the original:
7.5 Million Granted to Collaborative PROTO Project led by Charit to Study Pluri's PLX-PAD Cells for Osteoarthritis Treatment - GlobeNewswire

Posted in Regenerative Medicine | Comments Off on 7.5 Million Granted to Collaborative PROTO Project led by Charit to Study Pluri’s PLX-PAD Cells for Osteoarthritis Treatment – GlobeNewswire

Carson City School District experiencing teacher shortage; nationwide data points to burnout, low pay and behavior issues as culprits – Carson Now

Posted: September 8, 2022 at 2:22 am

Across the country, mass teacher shortages have been felt in seemingly every district, and the capital city is not immune.

There are currently 46 unfilled positions throughout the district, broken down as:

Teacher positions by study of currently unfilled include: elementary school, middle school science, middle school culinary arts, middle school math, middle school English, and middle school social studies.

To assist with the current teaching shortage, CCSD has re-hired some of our recently retired educators and increased the pay for substitute teachers, said Dan Sadler, associate superintendent of Human Resources for the district.

Additionally, some school sites have shuffled class schedules around to absorb the vacancies and provide support in creative ways, such as by buying teacher preps, which essentially means paying teachers to cover another classroom during their prep-time, which is generally spent grading, attendance, and lesson planning.

CCSD has a tiered system of substitute teachers currently assigned in our schools (emergency subs, daily subs, super subs, long term subs), said Sadler. CCSD is always looking for additional people who may be interested in supporting our schools.

In neighboring Washoe County, it was announced only days before the beginning of school that the district was short by more than 200 for classified teachers, and the district had to reassign multiple administrative positions and TOSAs (Teacher on Special Assignment) to cover classrooms.

There are a lot of issues contributing to why there are teacher shortages throughout the country, including burnout, low pay, behavior issues from both students, parents and the public alike, and more.

A Look at the Issues

There are currently over half a million fewer educators in Americas public schools today than there were prior to the pandemic.

Over 90 percent of teachers have reported that burnout is a serious problem within the teaching profession, and 55 percent have stated they are ready to leave their profession earlier than previously planned.

This is a five-alarm crisis, said National Education Association President Becky Pringle. We are facing an exodus as more than half of our nations teachers and other school staff are now indicating they will be leaving education sooner than planned. If were serious about getting every child the support they need to thrive, our elected leaders across the nation need to address this crisis now.

Behavior Issues: Student, Parent, Public

76 percent of teachers stated that student behavioral issues as well as a lack of respect from parents and the public are serious issues.

When it comes to the behavior of students, 87 percent of public schools agreed that these issues stem directly from the pandemic, and include classroom disruptions, acts of disrespect toward teachers and staff, rowdiness outside of the classroom, and the prohibited use of electronic devices.

Public schools reported needing more support for student and/or staff mental health (79 percent), training on supporting students socio-emotional development (70 percent), hiring of more staff (60 percent), and training on classroom management strategies (51 percent).

Across the country, and locally, school board meetings and public schools have been over run by a tiny but extremely vocal minority of individuals who spouted unsubstantiated claims that teachers were indoctrinating students into hating America, forcing vaccines upon them, and general abuses.

Carson City board members and educators faced these issues as well, with public commenters, the vast majority of whom did not have school-aged children, attending board meetings for months at a time stating that the schools were killing children by requiring them to wear masks, pushing Marxism on students, and asking for school board members to be fired because the COVID-19 vaccine contains aborted fetal cells, monkey kidney cells, E-Coli, animal parts, spermicide, and more.

While issues surrounding masks and vaccines have seemingly fallen away in recent months, school boards across the country are facing a new push from these vocal minorities: banning books.

Book banning is at an all time historic high, with a record-breaking 1,145 books being banned by school districts across the country between July 1, 2021 and March 31, 2022.

The books currently being banned throughout the country almost exclusively focus on LGBTQ+ issues, followed by the history of racism and oppression felt by certain groups within the U.S., such as Native and Black Americans.

Low Pay, Less Teaching Degrees

Currently, 78 percent of teachers have stated that low pay is a serious issue, and when it comes to pay, U.S. teachers now are making less than their counterparts 50 years ago.

In 1972, the average teacher in America was making $10,174 per year, which, in todays dollars, is the equivalent of over $72,000.

Today, however, that number has lowered to $65,000 with a huge range between states. For example, the average teacher salary in New York is almost $90,000 per year, while Mississippi teachers make an average of only $47,000.

Nevada teachers fall somewhere in between with an average salary of $56,676, and a typical range of between $47,000 to $69,000. By comparison, in the 70s, Nevada teachers made the equivalent of $65,315 in todays dollars.

In addition, the number of college students engaging in education teaching programs has simply, and drastically, decreased.

Between 2008 and 2019, the number of students graduating from teaching programs decreased by over a third. Up until the early 2010s, the number of these degrees were relatively stable, but began dropping quickly after.

Reasons attributed to this decrease in interest are linked to poor pay, heavy workloads, as well as political demonization.

Regardless of the reason behind the teacher shortages, one thing is clear: with more teachers leaving the profession than on boarding, those who will suffer the most are the students left in the gap.

The rest is here:
Carson City School District experiencing teacher shortage; nationwide data points to burnout, low pay and behavior issues as culprits - Carson Now

Posted in Nevada Stem Cells | Comments Off on Carson City School District experiencing teacher shortage; nationwide data points to burnout, low pay and behavior issues as culprits – Carson Now

Engensis Gene Therapy for ALS Found Safe in Small Phase 2a Trial |… – ALS News Today

Posted: September 8, 2022 at 2:20 am

Repeated muscle injections with Engensis (VM202), Helixmiths investigational non-viral gene therapy, were generally safe and well-tolerated in people with amyotrophic lateral sclerosis (ALS), according to top-line data from a Phase 2a clinical trial.

While the sample size was too small to determine the therapys efficacy, muscle biopsies were collected and will be examined to further evaluate the underlying mechanisms of Engensis.

These data suggest that high dose, repeated treatments of Engensis, were safe and well tolerated, providing a great deal of flexibility in designing dosing schemes for future clinical studies, Helixmith stated in a company press release.

Trial analysis will continue once the full dataset is available, and the company plans to present such findings at a future conference. The next steps for Engensis development will be determined at that time.

Engensis is a non-viral gene therapy that uses Helixmiths proprietary small circular DNA molecule to deliver the hepatocyte growth factor (HGF) gene to cells in the muscle environment.

HGF provides instructions to produce a protein of the same name that helps the body form new blood vessels, prevents muscle loss, and promotes the growth and survival of nerve cells. The therapyis delivered via intramuscular (into-the-muscle) injections.

Helixsmith believes that by increasing HGF production, Engensis has the potential to promote nerve cell and muscle regeneration, thereby countering the progressive loss of motor control that characterizes ALS.

The therapy has been granted orphan drug and fast track designations by the U.S. Food and Drug Administration, both of which are intended to speed its clinical development and regulatory review.

A previous open-label Phase 1/2 trial (NCT02039401) found that four once-weekly intramuscular injections of Engensis (to a total dose of 64 mg) were safe and well-tolerated among 18 ALS patients. Signs that the therapy could slow disease progression were also observed.

These promising findings prompted the launch of a placebo-controlled Phase 2a trial, called REViVALS-1A (NCT04632225), which began patient enrollment last year. A total of 18 ALS patients experiencing motor symptoms in their limbs for four years or less were recruited at four sites in the U.S. and one in Korea.

Participants were randomized in a 2:1 ratio to receive three cycles of either Engensis or a placebo: at studys start, at two months, and at four months. Each cycle consisted of two days of injections to upper and lower limb target muscles, spaced two weeks apart (64 mg total of Engensis or a placebo).

This meant that Engensis-treated patients received a total of 192 mg of medication over the four-month period. All participants were monitored for six months from the studys start.

The trials main goal was to assess the safety and tolerability of Engensis, while efficacy measures were included as exploratory outcomes. These included changes in disability, muscle and lung function, survival, ALS-specific health-related quality of life, and the levels of muscle shrinkage biomarkers.

Top-line data showed that the investigational treatment was generally safe and well-tolerated, with no difference in the frequency of adverse events observed between the Engensis and placebo groups (83% for each).

One case of bronchitis a condition characterized by inflammation in the main airways of the lungs due to infection was observed in the Engensis group but was determined unrelated to treatment.

Injection site reactions were reported by 50% of Engensis-treated patients and 66.7% of those in the placebo group. Most of these reactions were mild or moderate in severity and temporary; no participant discontinued treatment due to the number of injections.

According to Helixmith, efficacy was unable to be evaluated due to the fact that four participants dropped out early from the small study.

Still, muscle tissue biopsies were obtained from injection sites to undergo analyses of muscle atrophy (shrinkage) biomarkers and others.

Since data on Engensis underlying mechanisms have been largely based on animal models, these results are expected to provide valuable information on the understanding of the mechanisms of actions of Engensis, and its effects on the [activity] of human genes, which will greatly help in the development of innovative medicines, the company stated in the release.

Helixmith greatly appreciates the generous and eager participation of the ALS patients, the company added.

Engensis is also being investigated across a range of conditions associated with deficits in circulation, and nerve and/or muscle damage, such as diabetic neuropathy, coronary artery disease, and Charcot-Marie-Tooth disease.

More than 500 patients have been treated with Engensis to date across 10 clinical trials and six different diseases, according to Helixmith. Data from these studies have also supported the therapys favorable safety profile and its ability to increase HGF production.

Link:
Engensis Gene Therapy for ALS Found Safe in Small Phase 2a Trial |... - ALS News Today

Posted in Gene therapy | Comments Off on Engensis Gene Therapy for ALS Found Safe in Small Phase 2a Trial |… – ALS News Today

A new gene therapy based on antibody cells is about to be tested in humans – MIT Technology Review

Posted: September 8, 2022 at 2:20 am

So far, Bcells havent gotten the same attentionindeed, genetically engineered versions have never been tested in a human. Thats partly because engineering B cells is not that easy, says Xin Luo, a professor at Virginia Tech who in 2009 demonstrated how to generate B cells that have an added gene.

That early work, carried out at Caltech, explored whether the cells could be directed to make antibodies against HIV, perhaps becoming a new form of vaccination.

While that idea didnt pan out, now biotech companies like Immusoft, Be Biopharma, and Walking Fish Therapeutics want to harness the cells as molecular factories to treat serious rare diseases. These cells are powerhouses for secreting protein, so thats something they want to take advantage of, says Luo.

Immusoft licensed the Caltech technology and got an early investment from Peter Thiels biotech fund, Breakout Labs. Company founder Matthew Scholz, a software developer, boldly predicted in 2015 that a trial could start immediately. However, the technology the company terms immune-system programming didnt turn out to be as straightforward as coding a computer.

Ainsworth says Immusoft had to first spend several years working out reliable ways to add genes to B cells. Instead of using viruses or gene editing to make genetic changes, the company now employs a transposona molecule that likes to cut and paste DNA segments.

It also took time to convince the FDA to allow the trial. Thats because its known that if added DNA ends up near cancer-promoting genes, it can sometimes turn them on.

The FDA is concerned if you are doing this in a B cell, could you develop a leukemia situation? That is something that they are going to watch pretty closely, says Paul Orchard, the doctor at the University of Minnesota who will be recruiting patients and carrying out the study.

The first human test could resolve some open questions about the technology. One is whether the enhanced cells will take up long-term residence inside peoples bone marrow, where B cells typically live. In theory, the cells could survive decadeseven the entire life of the patient. Another question is whether theyll make enough of the missing enzyme to help stall MPS, which is a progressive disease.

Go here to see the original:
A new gene therapy based on antibody cells is about to be tested in humans - MIT Technology Review

Posted in Gene therapy | Comments Off on A new gene therapy based on antibody cells is about to be tested in humans – MIT Technology Review

Page 234«..1020..233234235236..240250..»